Medicine and Health

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

J. Cortés, S. A. Hurvitz, et al.

Discover the groundbreaking results of the DESTINY-Breast03 trial, where trastuzumab deruxtecan (T-DXd) demonstrated remarkable efficacy over trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer treatment. With a follow-up of 41 months, T-DXd achieved a median overall survival of 52.6 months, changing the landscape of breast cancer therapy. This impactful research was conducted by an esteemed group of authors.

00:00

Playback language: English

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

K. Shitara, Y. Bang, et al.

Medicine and Health

Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

N. Harbeck, E. Ciruelos, et al.

Political Science

'Climate change concerns human survival...and justice in our international community': A corpus-based positive discourse analysis (PDA) of the largest developing nation's global involve/engagement discourses (re)told in interpreting

C. Gu

Medicine and Health

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

D. H. Ryan, I. Lingvay, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny